At the highest dose of 12 mg retatrutide, the average weight loss after 48 weeks was 24.2% with reduction up to 30% from the baseline weight in 25% of participants
In December 2023, a new study reported that in patients who had cardiovascular disease and obesity, but not diabetes, semaglutide was able to reduce the risk of heart attack, stroke, or death by 20%
Transgenic = 5xFAD
The ontological terms shared with the primary network of retatrutide included autism, S-adenosylhomocysteine hydrolase deficiency, cysteine and methionine metabolism, betaine metabolism, disorders of folate metabolism and transport, glyoxylate metabolism, and glycine degradation
The DM control group consisted of patients with T2DM who were prescribed insulin or glucose-lowering drugs but not incretin-based drugs (GLP-1 RAs or DPP-4 inhibitors)